ACAD
Acadia Pharmaceuticals·NASDAQ
--
--(--)
--
--(--)
5.47 / 10
Netural
Fund‑flow metrics are positive (overall inflow ratio ~0.50) except extra‑large trades, yielding a good flow score. Analyst consensus is 71% Buy, 14% Strong Buy and 14% Neutral, though historical win rates vary, leading to a neutral sentiment rating.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
14%
Buy
71%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-02-26
InstitutionRBC Capital
Times predicted5
Historical Win Rate40.0%
What is the analyst consensus for ACAD?
- ACAD holds a Bearish analyst rating, with 71% of experts assigning a Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 5.47/10 (Netural).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
